Back to today’s briefing

Story perspectives

Analysts Recommend Natera; Explore 5 Alternative Stocks

1/28/2025

40 7

Summary

Analysts Evaluate Stocks

Wall Street's top analysts are keeping a close eye on the stock market, with Myriad Genetics earning a cautious "Hold" rating, while Natera shines with a promising "Buy." Yet, savvy investors might want to explore five alternative stocks that experts believe offer even greater potential for growth.

Summary

Natera's Stock Surge

Natera's stock is gaining momentum as analysts boost its price target, with Goldman Sachs raising it from $160 to $190, suggesting a promising 14.98% upside. Despite a recent "sell" downgrade from StockNews.com, the overall sentiment remains a "Moderate Buy," with an average target of $165.88, showcasing robust institutional confidence in the company.

History

Historical Context

The cautious stock ratings for Myriad Genetics and Natera reflect a broader trend in the biotech sector, reminiscent of the late 1990s dot-com boom. During that era, rapid advancements and speculative investments led to volatile market behavior, highlighting the importance of due diligence in emerging industries.

1 of 3

Analysts Evaluate Stocks

Wall Street's top analysts are keeping a close eye on the stock market, with Myriad Genetics earning a cautious "Hold" rating, while Natera shines with a promising "Buy." Yet, savvy investors might want to explore five alternative stocks that experts believe offer even greater potential for growth.

1 / 3